Medalchemy, a technology-based company from the University of Alicante (UA), certified by the Group's GMP in Alicante, has obtained approval from the health authorities (AEMPS) to manufacture medicinal cannabis extracts as products with active pharmaceutical ingredients (API). According to the UA, it is the first European company licensed to manufacture and market medicinal cannabis active ingredients with THC.
The GMP license extension allows Medalchemy to manufacture medicinal cannabis APIs containing delta 9-tetrahydrocannabinol (THC) for commercial purposes.
This was announced by EMMAC Life Sciences Group, Europe's leading independent cannabis company, which includes Medalchemy, becoming the first European cannabis company licensed to manufacture and market these active ingredients.
Based in the Alicante Science Park, Medalchemy will immediately begin production and distribution of a range of medicinal cannabis products across multiple European jurisdictions, as well as the supply of white-label medicinal cannabis products.
This announcement, which the AU has hailed as historic, supports EMMAC's business-to-business operations, expands its medical and wellness operations, and confirms its position as Europe's leading vertically integrated cannabis company, with full control of the supply chain.
Antonio Costanzo, CEO of EMMAC, stated that "this is a historic announcement for EMMAC, and is the realization of our vision of creating a vertically integrated multinational operation."
"This milestone will position EMMAC as a trusted leader in the European medicinal cannabis market and is a testament to the continued innovation and excellence at Medalchemy, as we now focus on increasing our medicinal cannabis export production to meet growing patient demand," he added.
by 
